Sean P. Reilly, RPh, PharmD

ad1adv@r.postjobfree.com • 713-***-****

LinkedIn URL • Oro Valley, AZ 85737

Clinical Pharmacy Specialist – Oncology / Hematology

Highly skilled Clinical Pharmacy Specialist with years of experience treating patients with the aims of conveying empathy and compassion and optimizing curative potential while concomitantly minimizing treatment- and disease-related side effects and toxicities.

Dedicated, innovative, results-oriented Hematology and Oncology Clinical Pharmacy leader with expertise in clinical management and progressive treatment of patients with a variety of solid tumors, hematologic malignancies, and non-malignant hematologic disorders. Experience with research protocols, including both industry and cooperative studies allowing exposure to state-of-the-art clinical trials and novel drug therapies. Exceptional interpersonal communication skills, both oral and written, used to educate patients, families, and team members to promote excellence in pharmacologic management, to build and fortify strong relationships with the organization, patients, partners, and the community. A significant contributor to antineoplastic therapy-related policy and procedure development, maintenance, and management.

Areas of Expertise

Oncology

Benign and Malignant Hematology

Clinical Pharmacy Practice

Healthcare Industry / Hospitals

Pharmaceutical Industry

Leadership & Team Building

Infectious Diseases

Medical Liaison

Clinical Pharmacology

Medication Therapy Management

Healthcare Management

Patient Counseling

Clinical Research

Protocol Development

Patient / Staff Education

Accomplishments

Collaborated with primary investigators and associated medication manufacturers to conduct all phases of clinical trials involving human subjects with related disease or condition and submission of documentation to the manufacturer and/or IRB, as appropriate, for numerous protocols.

At Texas Specialty Hospital, identified noncompliance with USP 797 guidelines and Texas Board of Pharmacy regulations, and proposed steps to mitigate and correct problems to bring department into compliance, receiving accolades from Texas Board of Pharmacy compliance investigator for project management of anteroom and clean room construction, completing ahead of schedule and under budget.

At Southampton Medical Group, designed and launched opening of ambulatory infusion center complete with nursing and patient care areas, and a pharmacy department capable of supporting and managing clinical trials and expanded access programs, secure and continuously temperature-regulated drug storage, and sterile compounding of aseptic admixtures and hazardous medications.

At both Ben Taub General Hospital and Parkview Cancer Institute developed formal Hematology/Oncology Clinical Pharmacy Service Lines and consult services, structured ASHP compliant educational programs for student and resident rotations, originated several hundred comprehensive ASCO, MASCC, and NCCN guideline-based, disease-specific chemotherapy protocols, and guided translation to electronic format for incorporation into Epic Beacon software.

Career Experience

Kaiser Permanente of Washington, Renton, WA 8/2022 – 02/2023

Hematology / Oncology Clinical Pharmacy Specialist

Implemented a program with the goals of improving three key components of pharmaceutical care: (1) Patient satisfaction scores, (2) Provider adherence and utilization of organizational oncology pathways, evidence- and guideline-based medicine, and (3) Cost containment. As the oncology subject matter expert for the Prior Authorization Help Desk team, managed requests for pharmaceuticals used to treat cancer (biological agents, growth factors, immunotherapies, antineoplastics, etc.). Reviewed patient-specific information including pathology reports, cytometry, and molecular testing, next generation sequencing, etc., to confirm diagnosis, age, performance status, co-morbidities, stage, grade, and other information necessary to evaluate appropriateness of therapy, confirm therapy is concordant with recommended sequence outlined in the pathway, and/or national guidelines, FDA approved- and/or off-label indications, as appropriate, and with consideration of the patients’ insurance provider (Medicare Part B, Medicare Part D, and commercial insurance). If/when discordance, and/or a therapeutically equivalent, yet more cost-effective treatment is identified, or if a less costly, formulary-preferred biosimilar is available, engaging the prescriber in a peer-to-peer discussion is implemented and alternatives are shared.

Parkview Regional Medical Center, Fort Wayne, IN 6/2017 – 3/2022

Hematology / Oncology Clinical Pharmacy Specialist

As part of multi-disciplinary team, and in collaboration with Hematology and Medical Oncology treatment teams, provided direct care for patients with a variety of solid tumors, hematologic malignancies, and non-malignant hematologic disorders. Guided and supported patient care in clinics, outpatient ambulatory infusion center, and inpatient clinical settings, managing all stages of patient treatment, including comprehensive progress notes, complete with details on past, planned, and current treatment regimen(s) and information on each antineoplastic agent with recommendations for monitoring, supportive care, dosing, and dose modification recommendations, as appropriate. Offered care for a variety of oncology diagnoses and contributed to industry and cooperative studies based on numerous research protocols, allowing exposure to state-of-the-art treatment protocols and new drugs in development. Managed surgical oncology needs of patients using innovation and technology to provide advanced practice medicine. Created guidelines and best practice-based chemotherapy protocols. Educated patients, physicians, pharmacy and nursing colleagues, and pharmacy students and residents.

In first three years of service, received over 25 accommodations through submission of ‘Recognition of Excellence’ awards from employee and physician colleagues.

Created a Hematology / Oncology Clinical Pharmacy Service Line at state-of-the-art cancer center.

Advanced development of a comprehensive and guideline-based chemotherapy treatment protocol template and adapted 300+ protocols for incorporation into EMR (Epic/Beacon software), with hyperlinks to studies / references on which protocols are based, antineoplastic agent and disease state specific recommended labs, monitoring, hold parameters, and supportive care.

Improved safety and quality of patient service by developing didactic oncology rotations for pharmacy students and residents.

Performed Medication Utilization Review and Assessment for formulary consideration and developed, managed, and maintained antineoplastic therapy-related policy and procedures.

Baylor College of Medicine, Houston, TX 8/2012 – 5/2017

Hematology / Oncology Clinical Assistant Professor

Provided practical instruction designed to give both lecture-based and on-the-job training and experience working in professional environment. Established program covering topics related to hematology and oncology using innovative learning formats, including lessons and lectures on Pharmacology of Antineoplastic Chemotherapy and Supportive Care Medications, Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neuropathy, Chemotherapy Induced Dermatologic and Infusion Reactions, Chemotherapy Induced Cardiotoxicity, Hypercalcemia of Malignancy, Tumor Lysis Syndrome, Neutropenic Fever, Colony Stimulation Factors, and Pain Management. Served as preceptor for pharmacy students and residents.

Developed and delivered lecture series for Baylor Hematology / Oncology Department Attending Physicians, Fellows, Residents, and Medical Students encompassing variety of topics related to pharmacology of antineoplastic chemotherapy, oncologic emergencies, and supportive care.

Ben Taub General Hospital – Harris Health System, Houston, TX 12/2011 – 12/2016

Hematology / Oncology Clinical Pharmacy Specialist

Provided leadership in clinical pharmacy management, setting the example for excellence in patient care and ensuring safety for hematology and oncology patients, including recommending / ordering supportive care and laboratory testing, evaluating results, and providing therapy recommendations, with unwavering adherence to all regulatory rules and requirements and exercising fiscal responsibility in terms of medication selection, standard of care, revenue generation and expenses. Collaborated with Section Chiefs and advised providers on product and protocol selection, dose adjustment recommendations for advanced age, impaired end organ function, and treatment intent, side effects and toxicities inherent in drug class and/or individual agent, and helped formulate plan to monitor, review, and evaluate treatment effectiveness. Monitored patients for side effects, assessed for drug interactions, and advised on pharmaceutical mitigation when appropriate. Composed detailed progress notes on each patient receiving therapy, admitted with complications arising from treatment, on clinical trials, and as requested through the Clinical Pharmacy Consult Service, the Hematologists and/or Oncologists. Conducted instruction to patients regarding medications and disease state and to pharmacy and nursing staff.

Reduced cost to treat inpatients by $12K+ per cycle and outpatients by $2,300+ per cycle and saved organization over $260K per year by developing 5-day Azacitidine outpatient protocol.

Spearheaded NCCN Guideline-supported transition from a high-dollar NK1-receptor antagonist-based antiemetic regimen employing Aprepitant®, to the more economical and more effective olanzapine-based antiemetic regimen for all patients receiving highly emetic, and for high-risk patients receiving moderately emetic chemotherapy, saving the organization over $400,000 annually.

Partnered with two Hematology/Oncology PharmD Colleagues to develop a training module and exam for inpatient central pharmacist colleagues, designed to educate, improve safety, and establish a baseline of knowledge and experience to oversee preparation and dispensing of antineoplastic chemotherapy.

Developed a Carboplatin Dosing Protocol and provided associated education to ensure safety and adherence with FDA, ASCO, and NCCN guideline-based dosing recommendations.

Created a protocol for Cisplatin administration intended to enhance patient safety and reduce severe side effects and toxicities including electrolyte abnormalities, nephrotoxicity, and ototoxicity.

Designed and developed over 400 comprehensive, guideline-based chemotherapy treatment protocols complete with hyperlinks to the studies / references forming protocols’ bases, antineoplastic agent and disease state specific recommended labs, monitoring, hold parameters, and supportive care.

Collaborated with the Infectious Disease, Hematology and Oncology section chiefs to create a template for treatment of Neutropenic Fever with concurrent issuance of presentation to educate physicians, nurses, Emergency Department, and pharmacy personnel on the identification and treatment of Neutropenic Fever and guidance on accessing and assigning the Neutropenic Fever order set in the EMR, saving an enormous number of lives.

In collaboration with the Hematology and Oncology section chiefs, created a Pharmacy-Based Dose Rounding Protocol, identifying the top 12 high-dollar antineoplastic agents, which, with pre-defined parameters, were to be rounded to the closest vial size intended to preserve resources in a time of critical drug shortages, and to recognize substantial cost containment (over $500.000/year).

In partnership with Hematology and Oncology section chiefs, established alternative medications, treatment protocols, and alternative dosing schema to combat effects of the national drug shortage crisis.

Established Hematology / Oncology Clinical Pharmacy Service Line and Consult Services for one of the largest publicly owned hospital systems in the country.

Additional Experience

Hematology / Oncology Clinical Pharmacist, St. Luke’s Episcopal Hospital, Houston, TX

Lead Clinical Pharmacist, River Oaks Hospital, Houston, TX

Director of Pharmacy, QVL Pharmacy, Houston, TX

Director of Pharmacy / Pharmacist in Charge, Texas Specialty Hospital at Houston / Omnicare, Houston, TX

General Manager / Pharmacist in Charge, Park Infusion Care, Houston, TX

Clinical Pharmacy Manager / Pharmacist in Charge, On Col Therapeutics / Healix Infusion Services, Houston, TX

Clinical Pharmacy Manager / Pharmacist in Charge, Southampton Medical Group, Houston, TX

Education

Doctor of Pharmacy (PharmD)

University of Texas at Austin, College of Pharmacy, Austin, TX

Bachelor of Science, Pharmacy

University of New Mexico, College of Pharmacy, Albuquerque, NM

Licenses & Certifications

Registered Pharmacist – Arizona, License #S026732: Effective 10/10/2023, Exp. 10/31/2024

Registered Pharmacist – Indiana, License #260274281: Effective 10/4/2017, Exp. 6/30/2024

Registered Pharmacist – Texas, License #35235: Effective 3/1/1995, Exp. 12/31/2024

Registered Pharmacist – Washington, License #PH61281319: Effective 07/28/2022, Exp. 12/12/2023

Board Certified Oncology Pharmacist (BCOP). #5140109F, Iss. 1/1/2015, Exp. 12/31/2022

National Provider Identifier #134*******

Advanced Cardiac Life Support – American Heart Association, Exp. 12/2017

Aseptic Techniques for Pharmacists, Instructor

Basic Life Support, Exp. 03/2025

Cardiopulmonary Resuscitation – American Heart Association

How to Get a Job in a Different City, 05/2022

Immunization Certified Pharmacist, 11/2012

Instructors Course for Aseptic Techniques, 10/1999

Affiliations

Full Member, American College of Clinical Pharmacists (AACP)

Member, American Pharmacists Association (APhA)

Member, American Society of Health System Pharmacists (ASHP)

Member, Hematology / Oncology Pharmacists Association (HOPA)

Member, Multinational Association of Supportive Care in Cancer (MASCC)

Publications

1.“Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report,” Transfusion, October 2013

2.“Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.” American Journal Health Systems Pharmacy, January 2015

3.“Implementation of an integrated computerized prescriber order-entry system for chemotherapy in a multisite safety-net health system.” American Journal of Health Systems Pharmacy, March 2018

Community Development

Ronald McDonald House, Kindness Kitchen, 1/2020 – Present

YMCA Live-Strong, 5/2019 – Present

MD Anderson Cancer Center IRB 5, 3/2012 – 12/2016

AIDS Foundation Houston, 3/1999 – 10/1999

CASA de Esperanza, 10/1997 – 4/1998

Contact this candidate